Benzinga | Aug 19, 2020 09:57AM EDT

Citigroup Upgrades Cellectis to Buy, Raises Price Target to $32

Citigroup analyst Yigal Nochomovitz upgrades Cellectis (NASDAQ:CLLS) from Neutral to Buy and raises the price target from $15 to $32.